Lexeo reports interim data for heart condition gene therapy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. ORCL
2. ANT
3. SPY
4. FFAI
5. FFR
6. META
7. FICO
8. CART
9. LLY
10. TSLA

Go back to Lexeo reports interim data for heart condition gene therapy

Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy

January 12, 2026 7:00 AM EST

LX2020 generally well tolerated across ten participants with no clinically significant complement activation 

LX2020 transduction, transcription, and increased protein expression observed across participants with dose-dependent response; mean increase in PKP2 protein of 93% in low-dose cohort and 162% in high-dose cohorts

Arrhythmia burden stabilized or improved in majority of participants with dose-dependent response in non-sustained ventricular tachycardia and premature ventricular contractions

Company to host webcast today at 8:00 AM ET / 5:00 AM PT

NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) --... More